Outcomes in COVID-19 HuMax-IL8 studies

0 0.5 1 1.5+ All studies -6% 1 43 Improvement, Studies, Patients Relative Risk Mortality -6% 1 43 ICU admission -100% 1 22 RCTs -6% 1 43 Late -6% 1 43 HuMax-IL8 for COVID-19 c19early.org November 2025 FavorsHuMax-IL8 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] death 11/29 5/14 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk All studies -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk 1 HuMax-IL8 COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Effect extraction pre-specified(most serious outcome) Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] 11/29 5/14 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk All studies -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk 1 HuMax-IL8 COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -100% 2.00 [0.34-11.6] 9/18 1/4 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.45 Late treatment -100% 2.00 [0.34-11.6] 9/18 1/4 100% higher risk All studies -100% 2.00 [0.34-11.6] 9/18 1/4 100% higher risk 1 HuMax-IL8 COVID-19 ICU result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.45 Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] death 11/29 5/14 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk All studies -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk 1 HuMax-IL8 COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Effect extraction pre-specified(most serious outcome) Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] death 11/29 5/14 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk All studies -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk 1 HuMax-IL8 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Effect extraction pre-specified(most serious outcome) Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] 11/29 5/14 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Late treatment -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk All studies -6% 1.06 [0.46-2.47] 11/29 5/14 6% higher risk 1 HuMax-IL8 COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.9 Favors HuMax-IL8 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Stein (RCT) -6% 1.06 [0.46-2.47] death 11/29 5/14 Improvement, RR [CI] Treatment Control Stein (RCT) 3% 0.97 [0.35-2.67] death 8/29 4/14 Stein (RCT) -100% 2.00 [0.34-11.6] ICU 9/18 1/4 Stein (RCT) -107% 2.07 [0.92-4.65] no improv. 29 (n) 14 (n) HuMax-IL8 COVID-19 outcomes c19early.org November 2025 Favors HuMax-IL8 Favors control